(Reuters) - Xolair, given as an injection and known generically as
omalizumab, is approved to treat adults and adolescents age 12
and above for moderate to severe asthma.
The FDA has warned that anaphylaxis, a dangerous
inflammatory reaction characterized by shortness of breath,
rash, wheezing and low blood pressure, occurs in about one in
one thousand patients taking the medication.
Read more at Reuters.com Government Filings News
omalizumab, is approved to treat adults and adolescents age 12
and above for moderate to severe asthma.
The FDA has warned that anaphylaxis, a dangerous
inflammatory reaction characterized by shortness of breath,
rash, wheezing and low blood pressure, occurs in about one in
one thousand patients taking the medication.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment